July 02, 2026 article Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management Critical Reviews in Oncology/Hematology DOI: 10.1016/j.critrevonc.2026.105473 OpenAlex Authors 0 Author list not loaded yet. Cited by 0 stored of 0 References 11 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma 2024 New England Journal of Medicine article Medicine Cutaneous Melanoma Detection and Management Open access 538 citations Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials 2023 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access 135 citations Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma 2021 Annals of Oncology article Medicine Cutaneous Melanoma Detection and Management Open access 68 citations Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma 2023 Nature Reviews Clinical Oncology review Medicine Cutaneous Melanoma Detection and Management 50 citations Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma 2023 European Journal of Cancer article Medicine Cutaneous Melanoma Detection and Management Open access 35 citations Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo 2024 European Journal of Cancer article Medicine Cutaneous Melanoma Detection and Management Open access 33 citations Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy 2024 Journal of Experimental & Clinical Cancer Research article Medicine Cutaneous Melanoma Detection and Management Open access 30 citations Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma 2023 Cancer Discovery article Medicine Cancer Immunotherapy and Biomarkers 23 citations Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 2025 Nature Medicine article Medicine Cancer Immunotherapy and Biomarkers Open access 23 citations Lessons from neoadjuvant immunotherapy in melanoma: understanding antitumour immunity and tumour escape 2025 Nature reviews. Immunology review Medicine Cancer Immunotherapy and Biomarkers 17 citations Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures 2025 Cancer Immunology Immunotherapy article Medicine Cancer Immunotherapy and Biomarkers Open access 3 citations 11 results